| P2093 | author name string | Yasuo Mori | |
| | Goichi Yoshimoto | |
| | Hiromi Iwasaki | |
| | Katsuto Takenaka | |
| | Koichi Akashi | |
| | Toshihiro Miyamoto | |
| | Masutaka Furue | |
| | Koji Kato | |
| | Kensuke Sasaki | |
| | Konosuke Nagae | |
| | Kenjiro Kamezaki | |
| | Teppei Sakoda | |
| | Etsuko Yonemitsu | |
| | Yoko Kanamitsu | |
| P2860 | cites work | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 |
| | MyD88, an adapter protein involved in interleukin-1 signaling | Q28608950 |
| | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 |
| | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 |
| | Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 |
| | Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. | Q34434935 |
| | Subcutaneous Sweet syndrome in the setting of myeloid disorders: a case series and review of the literature | Q34582569 |
| | Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel | Q34626628 |
| | Characteristics of Sweet Syndrome in patients with acute myeloid leukemia | Q35688721 |
| | Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Q36915139 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors | Q38018908 |
| | Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib | Q38098593 |
| | Myelofibrosis discovered after diagnosis of Sweet's syndrome | Q40763359 |
| | JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 |
| | JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 |
| | The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis | Q42385052 |
| | The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 |
| | Bilateral toxoplasmosis retinitis associated with ruxolitinib | Q44909357 |
| | Ruxolitinib can mask symptoms and signs of necrotizing fasciitis | Q46176759 |
| | Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. | Q50518821 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. | Q53099028 |
| | Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes. | Q53381432 |
| | Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis. | Q53607106 |
| | Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. | Q54021770 |
| | Ponatinib-induced neutrophilic panniculitis. | Q54372623 |
| | JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. | Q54374933 |
| | Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia | Q57748971 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning | Q60710884 |
| | An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet's syndrome | Q71330470 |
| | Sweet's syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate | Q71744020 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis | Q81695156 |
| | Sweet syndrome associated with granulocyte colony-stimulating factor | Q81943837 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| P433 | issue | 18 | |
| P921 | main subject | myelofibrosis | Q1752571 |
| | ruxolitinib | Q7383611 |
| P304 | page(s) | 2481-2485 | |
| P577 | publication date | 2017-08-21 | |
| P1433 | published in | Internal Medicine | Q6047666 |
| P1476 | title | Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation | |
| P478 | volume | 56 | |